Hasil Pencarian (11778)
Halaman 229 / 236Vesatolimod has been used in trials studying the treatment of Hepatitis B and Chronic Hepatitis B.
Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
Vestipitant has been investigated for the treatment of Tinnitus.
Vestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. The enzyme is a homotetramer consisted of 4 monomers with …
Veverimer is under investigation in clinical trial NCT03390842 (Long-term Safety Extension to Study TRCA-301).
Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).
Vibecotamab is under investigation in clinical trial NCT05285813 (A Phase II Study of Vibecotamab (Xmab14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure).
Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant …
_Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1.[L12801] Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is g…
Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Vidofludimus is under investigation in clinical trial NCT03722576 (Vidofludimus Calcium for Primary Sclerosing Cholangitis).
VidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur.[L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a…
Vidupiprant has been used in trials studying the treatment and basic science of Asthma.
Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms.[L13616] It irreversibly inhibits the enzyme responsible for GAB…
Vilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1? True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxal…
Vilanterol is a selective long-acting ?2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma.[A7737] This is in response to the need for longer-acting ?2-adrenergic agonists to overcome poor patient complia…
Vilaprisan has been used in trials studying the treatment of Leiomyoma and Clinical Trial, Phase I.
Vilastobart is under investigation in clinical trial NCT04896697 (Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors).
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain[A6947]. Vilazodone …
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired.[A232488] By i…
Viloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation …
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less seve…
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Vincamine is a monoterpenoid indole alkaloid obtained from the leaves of *Vinca minor* with a vasodilatory property. Studies indicate that vincamine increases the regional cerebral blood flow.
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute l…
Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle…
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998]. It was initially approved in the USA in 1990's for the treatment of NSCLC…
Vinpocetine has been investigated for the treatment of Epilepsy.
Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.
Deskripsi belum tersedia.
Vinylglycine is an irreversible inhibitor of aspartate aminotransferase.
Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomyc…
Viper antivenom consists of antibodies derived from horses immunized and subsequently developed antibodies against snake venoms. ANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA o…
Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus evade the host immune…
Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. It was granted FDA orphan designation in January 2017 and investigated for the treat…
Virginiamycin is a streptogramin antibiotic similar to pristinamycin and quinupristin/dalfopristin. It is a combination of pristinamycin IIA and virginiamycin S1. Virginiamycin is used in the fuel ethanol industry to prevent microbial contamination and in liv…
Deskripsi belum tersedia.
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by ant…
VIS-410 is under investigation in clinical trial NCT03040141 (Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A).
Visilizumab has been investigated for the treatment of Ulcerative Colitis.
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library o…
Deskripsi belum tersedia.
Visugromab is under investigation in clinical trial NCT06059547 (Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer).